Physician profile
Geru Wu
NPI 1801153556
$1,393.13
in general payments reported to CMS, 2019-2025
14 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $107 · 2021: $152 · 2022: $514 · 2023: $175 · 2024: $33.26 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.00 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $212.73 | 2020-2025 | Mitraclip |
| Boston Scientific Corporation | $193.59 | 2019-2023 | Watchman Access System |
| Amgen INC. | $180.90 | 2019-2023 | |
| Abiomed | $154.15 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $150.70 | 2019-2023 | Farxiga |
| Cardiovascular Systems INC. | $135.31 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.57 | 2022-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $55.86 | 2020-2022 | |
| Biotronik INC. | $52.34 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.57 | 2020-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $40.86 | 2021-2023 | |
| Baxter Healthcare | $33.26 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Venclose INC. | $18.67 | 2020 | |
| Medtronic, INC. | $13.62 | 2023 | Selectsecure |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geru Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.